Exscientia starts trials of first AI-derived cancer immunotherapyExscientia was the first company to start human trials of a new drug designed using artificial intelligence (AI) Share XExscientia starts trials of first AI-derived cancer immunotherapyhttps://pharmaphorum.com/news/exscientia-starts-trials-of-first-ai-derived-cancer-immunotherapy/
AI drug discovery player 1910 Genetics debuts with $26m war chestThere’s a new kid on the block among companies using artificial intelligence in drug discovery, after 1910 Genetics Share XAI drug discovery player 1910 Genetics debuts with $26m war chesthttps://pharmaphorum.com/news/ai-drug-discovery-player-1910-genetics-debits-with-26m-war-chest/
Protein misfolding specialist Gain nets $40m from IPOGain Therapeutics has priced its initial public offering, raising more than $40 million for its computational drug discovery Share XProtein misfolding specialist Gain nets $40m from IPOhttps://pharmaphorum.com/news/protein-misfolding-specialist-gain-nets-40m-from-ipo/
Welsh startup Antiverse raises $2m for antibody discovery toolkitNew biotech Antiverse has raised seed funding of £1.4 million ($2 million) to develop its artificial intelligence-based platform Share XWelsh startup Antiverse raises $2m for antibody discovery toolkithttps://pharmaphorum.com/news/welsh-startup-antiverse-raises-2m-for-antibody-discovery-toolkit/
AI drug discovery firm Valence joins Parkinson’s disease pushCanada’s Valence Discovery has joined a University of Montreal-led project to try to find new drugs to treat Share XAI drug discovery firm Valence joins Parkinson’s disease pushhttps://pharmaphorum.com/news/ai-drug-discovery-firm-valence-joins-parkinsons-disease-push/
Alzheimer’s Research UK starts AI-based drug hunt with ExscientiaMedical charity Alzheimer’s Research UK has teamed up with artificial intelligence specialist Exscientia to find new drug treatments Share XAlzheimer’s Research UK starts AI-based drug hunt with Exscientiahttps://pharmaphorum.com/news/alzheimers-research-uk-starts-ai-based-drug-hunt-with-exscientia/
AI drug discovery biotech AbCellera eyes record IPOAbCellera Biologics has been in the spotlight since coming up with Eli Lilly’s COVID-19 antibody drug bamlanivimab, and Share XAI drug discovery biotech AbCellera eyes record IPOhttps://pharmaphorum.com/news/ai-drug-discovery-biotech-abcellera-eyes-record-ipo/
How the rare disease community has developed fertile ground for progressAmanda Barrell explores how a perfect storm of changing economics, advances in technology, and the increasing volume of Share XHow the rare disease community has developed fertile ground for progresshttps://pharmaphorum.com/views-analysis-patients/how-the-community-developed-fertile-ground-for-progress-in-rare-disease-drug-development/
BioNTech, InstaDeep plan joint lab for AI researchBioNTech may be deeply ensconced in the latter stages of its bid to bring a COVID-19 vaccine to Share XBioNTech, InstaDeep plan joint lab for AI researchhttps://pharmaphorum.com/news/biontech-instadeep-plan-joint-lab-for-ai-research/
